Daiichi Sankyo And Gustave Roussy Enter Innovative Research Collaboration For Dxd Adcs Ds-1062 And Patritumab Deruxtecan

Daiichi Sankyo And Gustave Roussy Enter Innovative Research Collaboration For Dxd Adcs Ds-1062 And Patritumab Deruxtecan

By, Admin 23 July 2020

Daiichi Sankyo Company, Limited (Hereafter, Daiichi Sankyo) And Gustave Roussy Announced A Multi-Year, Multi-Study Research Collaboration To Enrich And Further Enable The Development Of Ds-1062 And Patritumab Deruxtecan (U3-1402), Two Of Daiichi Sankyo&Rsquo;S Lead Dxd Antibody Drug Conjugates (Adcs), In Lung And Breast Cancer.The Collaboration Will Focus On Clinical And Translational Research, Including Potential Combination Strategies For Ds-1062, A Trop2 Directed Dxd Adc, In Patients With Advanced Non-Small Cell Lung Cancer (Nsclc), And For Patritumab Deruxtecan, A Her3 Directed Dxd Adc, In Patients With Metastatic Breast Cancer.&Ldquo;We Look Forward To Engaging And Collaborating With The Deep Expertise And Cutting-Edge Oncology Research Capabilities Of Gustave Roussy, The Premier European Cancer Center, To Further Advance Clinical Development Of Ds-1062 And Patritumab Deruxtecan,&Rdquo; Said Antoine Yver, Md, Msc, Aihp, Acca Paris, Global Head, Oncology R&Amp;D, Daiichi Sankyo. &Ldquo;This Innovative Research Program Includes Two Precision-Medicine Rich Phase 2 Trials Designed With An Adaptive Approach To Help Determine Which Patients Are Most Likely To Benefit From Our Adcs With Optimal Speed And Efficiency. Combination Therapy Strategies Will Also Be Explored In Other Studies.&Rdquo;&Ldquo;This Partnership Is Strategic For Gustave Roussy And It Brings Together All The Skills Which Are Essential For Top Quality Research In Oncology. Launching Clinical Trials To Test Two Promising Molecules In Advanced Non-Small Cell Lung Cancer And Metastatic Breast Cancer Is Essential For Diseases Which Unfortunately Have An Increasing Incidence And For Which There Is An Urgent Need To Make Progress,&Rdquo; Said Prof. Jean-Charles Soria, General Director Of Gustave Roussy. "It Is By Pushing The Boundaries Of Innovation That We Will Further Improve The Quality Of Care For Our Patients."

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!